United States securities and exchange commission logo





                              October 26, 2021

       Yizhe Wang, Ph.D.
       Chief Executive Officer
       LianBio
       103 Carnegie Center Drive, Suite 215
       Princeton, NJ 08540

                                                        Re: LianBio
                                                            Amendment No. 2 to
Registration Statement on Form S-1
                                                            Filed October 20,
2021
                                                            File No. 333-259978

       Dear Dr. Wang:

             We have reviewed your amended registration statement and have the
following
       comments. In some of our comments, we may ask you to provide us with
information so we
       may better understand your disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comments apply to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to these comments, we may have additional comments.

       Form S-1/A filed October 20, 2021

       Cover Page

   1.                                                   Please expand your
disclosure on the prospectus cover page to provide a description of
                                                        how cash is transferred
through your organization, as you have described beginning on
                                                        page 11. State whether
any transfers, dividends, or distributions have been made to date.
       Risk factors summary, page 6

   2.                                                   Please revise both the
risk factors summary and the Risk Factors section to move forward
                                                        the risks related to
doing business in the PRC so that such risks are prominently disclosed
                                                        within each section in
relation to other identified material risks.
   3.                                                   We refer you to both
the bullet in your risk factors summary section and your Risk Factor
 Yizhe Wang, Ph.D.
LianBio
October 26, 2021
Page 2
      disclosure beginning on page 91 where you discuss your current and future
audit reports
      in relation to the Holding Foreign Companies Accountable Act. We
acknowledge that
      these disclosures make reference to the Accelerating Holding Foreign
Companies
      Accountable Act. However, please revise these disclosures to discuss that
the U.S. Senate
      passed the Accelerating Holding Foreign Companies Accountable Act which,
if enacted,
      would require foreign companies to comply with PCAOB audits within two
consecutive
      years instead of three, thus reducing the time period for triggering the
prohibition on
      trading.
       You may contact Christie Wong at 202-551-3684 or Mary Mast at
202-551-3613 if you
have questions regarding comments on the financial statements and related
matters. Please
contact Lauren Hamill at 303-844-1008 or Celeste Murphy at 202-551-3257 with
any other
questions.



                                                          Sincerely,
FirstName LastNameYizhe Wang, Ph.D.
                                                          Division of
Corporation Finance
Comapany NameLianBio
                                                          Office of Life
Sciences
October 26, 2021 Page 2
cc:       Thomas Danielski
FirstName LastName